NEWS
12. July 2010
>RELDATA Named Tech Awards Circle Winner / Unified Block and File Storage Solutions Provider Selected ...
18. June 2010
>RELDATA Selected as AlwaysOn East Top 100 Winner for Cloud and Infrastructure Technology Unified Storage ...
7. June 2010
>On June 24, 2010, the 8th annual Grazia Equity Business Plan Competition was hosted at ...
5. June 2010
>immatics announces Phase II Results with its Therapeutic Cancer Vaccine IMA901 in Patients with Advanced ...
2. June 2010
>Online-Brillenhändler Mister Spex zählt zu "Red Herring 100 Europe" Unternehmen Red Herring Europe Award ...
2. June 2010
>immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 ...
16. February 2010
>immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine ...
4. February 2010
>XConnect revenue doubled in 2009 XConnect, the leader in next-generation interconnection and carrier ENUM-registry ...
1. February 2010
>Online-Brillenhändler Mister Spex hat 2009 Brillen und Kontaktlinsen für rund 4,5 Millionen Euro verkauft – ...
26. January 2010
>RELDATA UNIFIED STORAGE NAMED ONE OF “100 COOLEST CLOUD COMPUTING PRODUCTS” BY EVERYTHING CHANNEL’S CRN ...
20. January 2010
>RELDATA (www.reldata.com), a provider of software-centric unified storage solutions, announced today its new RELDATA Partner ...
14. January 2010
>HORIZONT und Statista starten Portal HORIZONTstats.de Premium-Initiative für Paid Content Auf HORIZONTstats.de gibt es ...
9. December 2009
>First Chip Supplier to Offer 4x4 MIMO Wi-Fi Devices Will Play Active Role in One ...
2. December 2009
>Conergy Solar Factory in Frankfurt (Oder): Three Years "Quality Made in Germany" Ramp ...
20. November 2009
>Investoren-Einstieg unterstützt weitere Wachstumsstrategie Der Stuttgarter Finanzinvestor Grazia Equity ist beim After Sales Dienstleister ...
16. November 2009
>Allzu viele Partner bei der Finanzierung können das Wachstum eines jungen Unternehmens stören. Es kommt ...
22. October 2009
>COPRO will sich mit allen Projekten in der virtuellen Welt Twinity präsentieren. Als erstes ...
19. October 2009
>Mit Mister Spex bringt Dirk Graber den Durchblick zurück. Wir haben ihn zu seiner Arbeit ...
5. October 2009
>Statistik-Portal startet heute sein Premium-Angebot, das für 29,90 Euro pro Monat die Verwendung exklusiver Daten ...
1. October 2009
>"Gründerszene ist sehr unterentwickelt" Von Claus G. Schmalholz Lothar Späth, zuletzt Vorsitzender der ...
29. September 2009
>immatics biotechnologies GmbH today announced the appointment of Dr Carsten Reinhardt as Chief Medical Officer ...
22. September 2009
>RELDATA Introduces Next Generation 9240i Unified Storage System Powered by Enhanced RELvos 2.4 Virtualization OS ...
16. September 2009
>Venture capital firms Venrock Associates, Accel Partners, Grazia Equity and Crescent Point Group all participated ...
9. September 2009
>Nanosolar Completes Panel Factory, Commences Serial Production Today Nanosolar demonstrated the completion of its ...
9. September 2009
>Nanosolar Unveils Nanosolar Utility Panel™ Technology In conjunction with today's inauguration of our panel-assembly ...
9. September 2009
>NREL Certifies 16.4% Nanosolar Foil Efficiency It was May 2006 when we last released ...
10. August 2009
>immatics biotechnologies GmbH today announced that the company obtained European patent protection for the composition ...
7. August 2009
>How creativity is helping the German capital cope with economic crisis. BERLIN — The ...
27. July 2009
>Portal will Informationen für Marketingentscheider bündeln Mit einem neuen Seitenkonzept will das Statistik-Portal „Statista“ ...
21. July 2009
>RELDATA Named a CRN Emerging Technology Vendor RELDATA's unified storage solutions provide channel partners ...
7. July 2009
>Ehemaliger Ministerpräsident arbeitet für Venture Capital-Geber: Lothar Späth berät Grazia Equity Prof. Dr. h.c. ...
7. July 2009
>Metaversum GmbH, developer of Twinity, the world’s first mirror world – a virtual world made ...
3. July 2009
>Grazia Equity Award für die beste Geschäftsidee an der HHL Von einer Charityplattform ...
30. June 2009
>Conergy sells solar portfolio with a capacity of 10.7 MWp ...
17. June 2009
>immatics biotechnologies significantly improves XPRESIDENT™ technology platform. immatics biotechnologies today announced the completion of ...
10. June 2009
>Australia: Planning Approval for 282 Wind Turbines EPURON reaches key milestone for the largest ...
8. June 2009
>Conergy Deutschland GmbH sells the Heimpersdorf megawatt solar park to investor Conergy Deutschland GmbH ...
5. June 2009
>Die zweite Auflage des Buches "IT-Governance in der Praxis" von den Autoren Andreas Rüter (Grazia ...
29. May 2009
>moviepilot.de: Führender personalisierbarer Entertainmentguide für Kino, DVD und TV schließt zweite Finanzierungsrunde ab Berlin, 29.05.2009 ...
19. May 2009
>Solarstrom von Conergy reduziert Kosten für Wasserversorgung in Kalifornien • 1,6 MWp Solarpark im ...
14. May 2009
>Statista startet Geschäftskunden-Angebot Statistik-Portal bietet umfassende Markenreports und kostengünstige Online-Umfragen Ausführliche Analysen zu ...
8. May 2009
>Solar energy from the region, for the region: Conergy Deutschland inaugurates a megawatt class thin-film ...
28. April 2009
>XCONNECT NAMES RICHARD SHOCKEY, ENUM PIONEER AND IP COMMUNICATIONS EXPERT, TO ADVISORY BOARD Appointment ...
27. April 2009
>RELDATA EXPANDS ITS SALES ORGANIZATION Industry Veteran Peter Cmaylo joins RELDATA as VP Sales ...
22. April 2009
>XCONNECT EXPANDS GLOBAL ALLIANCE FEDERATION SERVICES Innovations Bring Communications Service Providers More NGN ...
20. April 2009
>Must-have-Accessoires: Hält die Brille mit der It-Bag Schritt? Das Mister Spex "Brillen-Mode-Barometer" analysiert ...
8. April 2009
>Metaversum and Twinity has been elected a Red Herring 100 Europe Winner 2009 With ...
24. March 2009
>OVERGENCE SESSION MANAGER LATEST VOIP-PEERABLE DEVICE CERTIFIED XCONNECT-READY Testing for ENUM Query Compatibility Streamlines ...
2. March 2009
>immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell ...
24. February 2009
>Quantenna Raises $15 Million in Series D Financing Round Quantenna Communications, Inc., a leader ...
24. February 2009
>RELDATA AND XYRATEX ENABLE HETEROGENEOUS STORAGE RELDATA 9240 and Xyratex F6412E RAID system certification ...
26. January 2009
>immatics wins 29th German Industry’s Innovation Award (Innovationspreis der deutschen Wirtschaft) Tuebingen, January 26, ...
26. January 2009
>The Growing Market for Solar Cells Printing is playing a key role in ...
24. January 2009
>VC Investing Drops For 2008, But Green Grows Venture capital investment shrank in 2008 ...
21. October 2008
>Metaversum Awarded Funding in Co-space™ program in Singapore Metaversum, developer and operator of ...
5. September 2008
>Wowereit Opens Virtual Berlin in Twinity Metaversum GmbH, developer and operator of the ...
2. June 2010
immatics & National Cancer Institute
immatics enters Collaboration with the National Cancer Institute (NCI) to Advance the Development of IMA950 for Glioblastoma
Multi-target therapeutic cancer vaccine IMA950 to enter second clinical phase I study for glioblastoma, the most aggressive form of brain cancer
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer.
Under the terms of the agreement, CCR will sponsor and conduct a phase I trial of IMA950 which will be carried out at the National Institute of Health’s (NIH’s) Facility in Bethesda, Maryland, U.S. The phase I trial will evaluate IMA950 in stable or recurrence-free glioblastoma patients following standard radiochemotherapy with temozolomide.
The principal investigator of the study is Dr. Howard Fine, Chief of the Neuro-Oncology Branch at the National Cancer Institute. immatics will collaborate with CCR and will also be responsible for drug supply for the study as well as undertaking immunomonitoring of the treated patients.
This collaboration follows an agreement immatics signed with Cancer Research UK in February for the clinical development of IMA950 in glioblastoma. The Cancer Research UK sponsored study will treat newly diagnosed patients with IMA950 in combination with radio-chemotherapy while this study at the NCI will treat patients after successful radio-chemotherapy with standalone IMA950. The different protocols for these two studies should mean that they provide complementary data reflecting the different clinical situations experienced by glioblastoma patients.
Paul Higham, CEO of immatics said: “We are delighted to be collaborating with such a prestigious organization as the National Cancer Institute to help us to develop our third therapeutic vaccine, IMA950. Our ability to secure two such highly regarded collaborators to advance IMA950 into the clinic demonstrates the significant interest in immatics’ novel therapeutic vaccines and the need for a much improved treatment option for glioblastoma. We very much look forward to working with the NCI to further develop IMA950 and to evaluate how it may be of benefit in this devastating disease.”
About IMA950
IMA950 is a therapeutic cancer vaccine generated through immatics’ proprietary XPRESIDENT™ technology. It consists of 11 tumor-associated peptides (TUMAPs) which the immatics platform selected on the basis of their natural presentation by tumor tissue, overexpression in tumor vs. healthy tissue, immunogenicity and their relevance to tumor function. This unique approach to rationally designed therapeutic vaccines which are a combination of multiple, highly relevant tumor peptides is at the core of all immatics’ clinical programs.
For additional information on immatics please visit www.immatics.com or contact:
Katrin Eckert, Assistant to the Management
immatics biotechnologies GmbH
Phone: +49-7071-5397-110
E-mail: media@immatics.com
Citigate Dewe Rogerson
David Dible / Chris Gardner / Amber Bielecka
Phone: +44 207 638 9571
E-mail: david.dible@citigatedr.co.uk
About immatics
immatics biotechnologies is a clinical-stage biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901 has completed a phase II trial in renal cell carcinoma. immatics’ pipeline also includes IMA910, in phase II for colorectal cancer, and IMA950 which is being developed for glioma.
immatics’ technology platform rapidly generates defined therapeutic cancer vaccines which are based on multiple tumor-associated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines – comprising multiple peptides confirmed to be naturally presented by real tumor tissue – offer the prospect of greater effectiveness than existing cancer vaccine approaches. immatics’ products are ‘drug like’ with stable, off-the-shelf formulations and robust easily scalable manufacturing.
immatics is based in Tuebingen and Munich, Germany, and has raised more than €54 million in private equity in two financing rounds.
About NCI
The US National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI is the Federal Government's principal agency for cancer research and training. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.